Australia - inglese - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; magnesium stearate; sodium starch glycollate type a; maize starch; povidone; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - bosentan intas is indicated for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; maize starch; povidone; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - bosentan astron is indicated for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clopidogrel besilate, quantity: 112.1 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: mannitol; polyethylene glycol monomethyl ether; iron oxide red; stearic acid; hyprolose; purified talc; citric acid monohydrate; hypromellose; lactose monohydrate; microcrystalline cellulose; triacetin; crospovidone; titanium dioxide - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome: plidogrel is indicated in combination with aspirin for patients with: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). plidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, plidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: pectin; mannitol; isopropyl alcohol; hyprolose; purified talc; lactose monohydrate; purified water; triacetin; titanium dioxide; magnesium stearate; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: pectin; purified water; hyprolose; lactose monohydrate; triacetin; magnesium stearate; mannitol; purified talc; isopropyl alcohol; titanium dioxide; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified water; triacetin; mannitol; lactose monohydrate; magnesium stearate; hyprolose; isopropyl alcohol; purified talc; pectin; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: purified water; purified talc; triacetin; titanium dioxide; magnesium stearate; isopropyl alcohol; lactose monohydrate; hyprolose; pectin; mannitol; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified water; triacetin; isopropyl alcohol; hyprolose; pectin; purified talc; magnesium stearate; titanium dioxide; mannitol; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; pectin; hyprolose; magnesium stearate; purified talc; lactose monohydrate; triacetin; titanium dioxide; mannitol; purified water; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 10 mg - tablet, film coated - excipient ingredients: purified water; lactose monohydrate; titanium dioxide; isopropyl alcohol; pectin; magnesium stearate; triacetin; hyprolose; purified talc; mannitol; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.